An unprecedented wait for final FDA approval will drag on for two orphan lymphoma drugs, at least a little while longer, as the agency decides how to end the delays and prevent them from happening again.
James Pereira is a Technical Writer Senior Advisor with a focus on providing accurate and informative articles on a wide range of topics. With a background in health, safety, and science, James covers news and developments in these areas, providing valuable insights and analysis for readers. His work aims to educate and empower readers to make informed decisions and stay up-to-date on important issues.